Amarin (NASDAQ:AMRN) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Amarin (NASDAQ:AMRN) in a research note issued to investors on Wednesday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Amarin Trading Down 2.7 %

Shares of AMRN stock opened at $9.11 on Wednesday. The stock has a market cap of $187.06 million, a P/E ratio of -101.22 and a beta of 1.38. Amarin has a 1 year low of $7.08 and a 1 year high of $20.60. The stock has a 50 day simple moving average of $9.78 and a 200 day simple moving average of $10.44.

Amarin (NASDAQ:AMRN) last released its earnings results on Wednesday, March 12th. The biopharmaceutical company reported ($2.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.20) by ($1.20). Amarin had a negative net margin of 16.33% and a negative return on equity of 7.22%. The company had revenue of $62.31 million for the quarter, compared to the consensus estimate of $32.37 million. Analysts forecast that Amarin will post -0.15 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of AMRN. Arkfeld Wealth Strategies L.L.C. grew its holdings in Amarin by 52.6% during the 4th quarter. Arkfeld Wealth Strategies L.L.C. now owns 58,000 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 20,000 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new position in shares of Amarin during the fourth quarter worth $36,000. Generation Capital Management LLC bought a new stake in shares of Amarin in the fourth quarter worth $50,000. Stonepine Capital Management LLC acquired a new stake in Amarin in the fourth quarter valued at $55,000. Finally, New York State Common Retirement Fund bought a new position in Amarin during the 4th quarter worth $68,000. 22.25% of the stock is currently owned by institutional investors and hedge funds.

Amarin Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.